Translational research in nephrology: Chronic kidney disease prevention and public health

Clinical Kidney Journal

Volumn 8, Issue 6, 2015, Pages 647-655

  Brück, Katharina ^a   Stel, Vianda S ^a   Fraser, Simon ^b   De Goeij, Moniek C M ^a   Caskey, Fergus ^c   Abu Hanna, Ameen ^a   Jager, Kitty J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

CKD; Diabetes mellitus; Epidemiology; Hypertension; Physical activity

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIETARY INTAKE; END STAGE RENAL DISEASE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; LOWEST INCOME GROUP; NEPHROLOGY; NON COMMUNICABLE DISEASE; PHYSICAL INACTIVITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SALT INTAKE; SCREENING TEST; SECONDARY PREVENTION; SMOKING; TRANSLATIONAL RESEARCH;

EID: 84959347712     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv082     Document Type: Review

References (96)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chron-ic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
3. Global Burden of Disease study (GBD) 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171
4. Lopez AD, Williams TN, Levin A et al. Remembering the forgotten non-communicable diseases. BMC Med 2014; 12: 200
5. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. [Erratum appears in Lancet 2013; 381: 628. Lancet 2012; 380: 2095-2128
6. WHO. Global Health and Aging. Bethesda, MD: WHO, 2011
7. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272
8. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
9. Roth M, Roderick P, Mindell J. Kidney Disease and Renal Function. Leeds: NHS, 2011
10. WHO. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva: WHO, 2013
11. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ 2006; 174: 801-809
12. Thijssen S, Kitzler TM, Levin NW. Salt: its role in chronic kidney disease. J Ren Nutr 2008; 18: 18-26
13. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3: 226-236
14. Ortiz A. Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. Clin Kidney J 2015; 8: 14-22
15. Woolf SH. The meaning of translational research and why it matters. JAMA 2008; 299: 211-213
16. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010; 172: 517-524
17. Westfall JM, Mold J, Fagnan L. Practice-based research-'Blue Highways' on the NIH roadmap. JAMA 2007; 297: 403-406
18. Cooksey SD. A review of UK health research funding. London, UK: Crown Copyright, 2006, pp. 1-120.
19. Ogilvie D, Craig P, Griffin S et al. A translational framework for public health research. BMC Public Health 2009; 9: 116
20. Moses H III, Dorsey ER, Matheson DH et al. Financial anatomy of biomedical research. JAMA 2005; 294: 1333-1342
21. May C. Towards a general theory of implementation. Implement Sci 2013; 8: 18
22. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38
23. WHO. A Guide for Population-Based Approaches to Increasing Levels of Physical Activity: Implementation of the WHO Global Strategy on Diet, Physical Activity and Health. Switzerland: WHO, 2007
24. NICE. NICE Guidance Physical Activity. London: NICE, 2012
25. Food and Drug Administration. Mobile Medical Applications; Guidance for Industry and Food and Drug Administration Staff. 2015. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf (9 February 2015, date last accessed)
26. Jahns R-G Global Mobile Health Trends and Figures Market Report 2013-2017. Research2Guidance, 2010: 1-31
27. Cavill N, Kahlmeier S, Racioppi F (eds). Physical Activity and Health in Europe: Evidencefor Action. Denmark: World Health Organisation, 2006
28. Centraal Bureau voor de Statistiek. Gezondheidsenquete. The Hague: CBS, 2012
29. Scholes S, Mindell J. Chapter 2: Physical activity in adults. In Health Survey England 2012. 2013; 1-49
30. Milieuhygiene RvVe. http://www.nationaalkompas.nl/gezondheidsdeterminanten/persoonsgebonden/overgewicht/trend/2014 (22 April 2015, date last accessed).
31. Available from: http://www.nationaalkompas.nl/gezondheidsdeterminant en/persoonsgebonden/overgewicht/trend/
32. Lifestyles Statistics Team, Health and Social Care Information Centre. Statistics on Obesity, Physical Activity and Diet. Leeds: Health and Social Care Information Centre, 2014
33. Malhotra A, Noakes T, Phinney S. It is time to bust the myth of physical inactivity and obesity: you cannot outrun a bad diet. Br J Sports Med 2015; 49: 967-968
34. Kujala UM. Evidence on the effects of exercise therapy in the treatment of chronic disease. Br J Sports Med 2009; 43: 550-555
35. Laine J, Kuvaja-Kollner V, Pietila E et al. Cost-effectiveness of population-level physical activity interventions: a systematic review. Am J Health Promot 2014; 29: 71-80
36. Roux L, Pratt M, Tengs TO et al. Cost effectiveness of community-based physical activity interventions. Am J Prev Med 2008; 35: 578-588
37. Chen IR, Wang SM, Liang CC et al. Association of walking with survival and RRT among patients with CKD stages 3-5. Clin J Am Soc Nephrol 2014; 9: 1183-1189
38. Sietsema KE, Amato A, Adler SG et al. Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. Kidney Int 2004; 65: 719-724
39. Johansen KL, Painter P. Exercise in individuals with CKD. Am J Kidney Dis 2012; 59: 126-134
40. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011; Cd003236
41. Levin A, Hemmelgarn B, Culleton B et al. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179: 1154-1162
42. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). Nephrol Dial Transplant 2015; 30 (Suppl 2): ii1-142
43. Howden EJ, Coombes JS, Strand H et al. Exercise training in CKD: efficacy, adherence, and safety. Am J Kidney Dis 2015; 65: 583-591
44. Brawley LR, Rejeski WJ, King AC. Promoting physical activity for older adults: the challenges for changing behavior. Am J Prev Med 2003; 25 (3 Suppl 2): 172-183
45. WHO. Guideline: Sodium Intake for Adults and Children. Geneva: World Health Organization, 2012
46. WHO. Reducing Salt Intake in Populations: Report of a WHO Forum and Technical Meeting. Paris, France: WHO, 2006
47. Sanchez-Castillo CP, Warrender S, Whitehead TP et al. An assessment of the sources of dietary salt in a British population. Clin Sci (Colch) 1987; 72: 95-102
48. Webster J, Trieu K, Dunford E et al. Target salt 2025: a global overview of national programs to encourage the food industry to reduce salt in foods. Nutrients 2014; 6: 3274-3287
49. Webster JL, Dunford EK, Hawkes C et al. Salt reduction initiatives around the world. J Hypertens 2011; 29: 1043-1050
50. Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362: 590-599
51. Puska P, Vartiainen E, Tuomilehto J et al. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bull World Health Organ 1998; 76: 419-425
52. Vartiainen E, Sarti C, Tuomilehto J et al. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland? BMJ (Clinical Research Ed) 1995; 310: 901-904
53. Vartiainen E, Puska P, Pekkanen J et al. Changes in risk factors explain changesinmortality from ischaemic heart disease in Finland. BMJ (Clinical Research Ed) 1994; 309: 23-27
54. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011; 378: 380-382
55. McMahon EJ, Campbell KL, Bauer JD et al. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev 2015; 2: Cd010070
56. KDIGO. Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2: 85
57. Leonardis D, Mallamaci F, Enia G et al. The MAURO study: baseline characteristics and compliance with guidelines targets. J Nephrol 2012; 25: 1081-1090
58. McMahon EJ, Campbell KL, Mudge DW et al. Achieving salt restriction in chronic kidney disease. Int J Nephrol 2012; 2012: 720429
59. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
60. Smyth A, Dunkler D, Gao P et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. Kidney Int 2014; 86: 1205-1212
61. Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71: 159-166
62. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014; 370: 60-68
63. http://ec.europa.eu/health/tobacco/smoke-free-environments/index-en.htm (19 March 2015, date last accessed)
64. http://ec.europa.eu/health/tobacco/ex-smokers-are-unstoppable/index-en.htm (19 March 2015, date last accessed)
65. Durkin S, Brennan E, Wakefield M. Mass media campaigns to promote smoking cessation among adults: an integrative review. Tob Control 2012; 21: 127-138
66. Bala MM, Strzeszynski L, Topor-Madry R et al. Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev 2013; 6: Cd004704
67. Callinan JE, Clarke A, Doherty K et al. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2010; Cd005992
68. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ (Clinical Research Ed) 2002; 325: 188
69. Jamison DT, Summers LH, Alleyne G et al. Global health 2035: a world converging within a generation. Lancet 2013; 382: 1898-1955
70. WHO. WHO technical manual on tobacco tax administration, 2010. Geneva: WHO, 2010.
71. Bilano V, Gilmour S, Moffiet T et al. Global trends and projections for tobacco use, 1990-2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet 2015; 385: 966-976
72. Halimi JM, Giraudeau B, Vol S et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-1292
73. Athyros VG, Katsiki N, Doumas M et al. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013; 29: 1263-1274
74. Patel UD, Hernandez AF, Liang L et al. Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines-Heart Failure Program study. Am Heart J 2008; 156: 674-681
75. Naicker K, Liddy C, Singh J et al. Quality of cardiovascular disease care in Ontario's primary care practices: a cross sectional study examining differences in guideline adherence by patient sex. BMC Fam Pract 2014; 15: 123
76. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010; 33 (Suppl 1): S11-S61
77. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ (Clinical Research Ed) 1995; 311: 1595-1599
78. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131: 660-667
79. Renard LM, Bocquet V, Vidal-Trecan G et al. Adherence to international follow-up guidelines in type 2 diabetes: a longitudinal cohort study in Luxembourg. PLoS One 2013; 8: 1-9: e80162
80. Sloan FA, Bethel MA, Lee PP et al. Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes. Rev Diabet Stud 2004; 1: 29-38
81. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J Am Soc Nephrol 2006; 17 (Suppl 2): S90-SS7
82. Shamoon H, Duffy H, Fleischer N et al. The effect of intensive treatmentofdiabetesonthe developmentandprogression of long-term complicationsininsulin-dependent diabetes mel-litus. N Engl J Med 1993; 329: 977-986
83. Turner R. Intensive blood-glucose control with sulphonylur-eas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
84. de Boer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539
85. Aitken GR, Roderick PJ, Fraser S et al. Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010. BMJ Open 2014; 4: e005480
86. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33: 73-77
87. Pippias M, Jager KJ, Kramer A et al. The changing trends and outcomes in renal replacement therapy: results from the ERA-EDTA Registry. Nephrol Dial Transplant 2015; doi: 10.1093/ndt/gfv327
88. Nederlands Huisartsen Genootschap (NHG), Cardiovasculair risicomanagement (Tweede herziening). Huisarts Wet 2012; 55: 14-28. Available from https://www.nhg.org/standaarden/volledig/cardiovasculair-risicomanagement (April 2015, date last accessed)
89. Lopez-Vargas PA, Tong A, Sureshkumar P et al. Prevention, detection and management of early chronic kidney disease: a systematic review of clinical practice guidelines. Nephrology 2013; 18: 592-604
90. Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for pro-teinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101-3114
91. Levey AS, Schoolwerth AC, Burrows NR et al. Comprehensive public health strategies for preventing the development, progression, and complicationsofCKD: reportofanexpert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 2009; 53: 522-535
92. Turner G, Wiggins K, Johnson D. Cari Guidelines: Primary prevention of chronic kidney disease: blood pressure targets. Westmead: Kidney Health Australia, 2012
93. Schmitt KE, Edie CF, Laflam P et al. Adherence to antihyper-tensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 2010; 32: 541-548
94. Fraser SD, Roderick PJ, McIntyre NJ et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract 2013; 14: 88
95. Mehta RL, Cerda J, Burdmann EA et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for neph-rology. Lancet 2015; 385: 2616-2643
96. White SL, Polkinghorne KR, Cass A et al. Alcohol consumption and 5-year onset of chronic kidney disease: the AusDiab study. Nephrol Dial Transplant 2009; 24: 2464-2472